PODCAST | AAAS 2018 Live: Dr. Don Cleveland on Designer DNA Drugs

Carlos Faraco
Mar 23, 2018

In this episode, Dr. Carlos Faraco speaks with Dr. Don Cleveland of the University of California San Diego regarding his work on drug-based gene silencing therapies. Cleveland and the members of his lab use these therapies, also known as designer DNA drugs, to silence genes involved in the development of various neurodegenerative diseases such as Alzheimer’s, Huntington’s and Lou Gehrig’s disease. In addition to these familiar diseases, they also discuss how designer DNA drugs may help those suffering from chronic traumatic encephalopathy, a neurodegenerative disease affecting individuals with a history of repeated head injury, including athletes, military personnel, and domestic abuse victims. While the concept of chronic traumatic encephalopathy was first introduced in the early 1900s due to its prevalence in boxers, the cause of the disease has recently come under significant public scrutiny in the US due to several high-profile stories involving football players.

Participants

Host: Carlos Faraco, Ph.D., Neuroscience
2016-2018 Executive Branch Fellow at the National Institutes of Justice

Don Cleveland, Ph.D., Biomedical Sciences
Chair, Departmental of Cellular and Molecular Medicine, UCSD
Professor of Medicine, Neurosciences, and Cellular and Molecular Medicine, UCSD
Member, Ludwig Institute for Cancer Research

Executive Producer

Carlos Faraco, Ph.D., Neuroscience
2016-2018 Executive Branch Fellow at the National Institutes of Justice

This blog does not necessarily reflect the views of AAAS, its Council, Board of Directors, officers, or members. AAAS is not responsible for the accuracy of this material. AAAS has made this material available as a public service, but this does not constitute endorsement by the association.

Image: Don Cleveland / Ludwig Cancer Research

Carlos Faraco

Carlos is a neuroscientist whose academic work has primarily focused on developing novel human MRI methods to evaluate disease progression and incident risk in stroke and neurodegenerative disease patients. His current work as an AAAS S&T Policy fellow at the National Institute of Justice has focused on strategic planning and developing effective science communitcation strategies. He is also highly involved with Sci on the Fly as editor for the blog and executive producer for the podcast.

Disclaimer

This blog does not necessarily reflect the views of AAAS, its Council, Board of Directors, officers, or members. AAAS is not responsible for the accuracy of this material. AAAS has made this material available as a public service, but this does not constitute endorsement by the association.

Related posts

10/13/16
Access Denied
by Emily Monosson
03/27/17
Feedback: Turning on Directions
by Kyle Wesson
01/29/14
Sugary beverages and Uterine Cancer
by Judy Keen

Leave a comment

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
By submitting this form, you accept the Mollom privacy policy.

Subscribe to our blog